3rd mRNA Process Development and Manufacturing Summit Europe 2025

With the mRNA market projected to reach $63.28 billion by 2025, the global demand for mRNA vaccines and therapeutics is at an all-time high. Now more than ever, robust process development and manufacturing are essential to ensure patients have access to life-saving treatments. While the industry is making strides in continuous processing, advanced analytics, improved scalability, and innovative formulations, significant challenges remain, including controlling impurities, long manufacturing timelines, and navigating complex regulatory pathways for timely approvals.

The 3rd mRNA Process Development and Manufacturing Summit 2025 returns as Europe's premier industry-focused forum, dedicated to optimizing process development for mRNA therapeutics and vaccines. This event will address end-to-end process optimisation, regulatory compliance to streamline approvals, while also advancing scalable and cost-efficient manufacturing solutions, to support drug developers in delivering safer and more effective mRNA drugs to patients faster.

Bringing together leading experts from CEPI, Merck, CureVac, BioNTech, Altamira, Genevation, and more, this summit will showcase cutting-edge advancements in end-to-end process development and manufacturing to support the production of high-quality, cost-effective mRNA therapeutics at scale.

URLs:
Website: https://go.evvnt.com/2872917-0?pid=10018
Tickets: https://go.evvnt.com/2872917-2?pid=10018
Brochure: https://go.evvnt.com/2872917-3?pid=10018

Prices:
Drug Developer Pricing - Conference + Workshop Day: EUR 3897.00,
Drug Developer Pricing - Conference Only: EUR 2799.00,
Academic and Research Pricing - Conference + Workshop Day: EUR 3297.00,
Academic and Research Pricing - Conference Only: EUR 2399.00,
Solution and Service Provider Pricing - Conference + Workshop Day: EUR 4797.00,
Solution and Service Provider Pricing - Conference Only: EUR 3499.00

Speakers: Adithya Nair, Research Associate, University of Sheffield, Andal Murthy, Senior Scientist, AstraZeneca, Chijian Zuo, Vice President, CureMed Biomedical Technology, Covadonga Paneda, Chief Operating Officer, Altamira Therapeutics, Daniela Daubert, Senior Director Process Development, Ethris GmbH, Dietmar Lang, Senior Director - Platform Development, CureVac SE, Géza Jakab, Head of Vaccine Formulation and Adjuvant Platform, Ceva Sante Animale, Gilles Divita, CEO, Divincell, Harris Makatsoris, Founder, Centillion Technology Ltd., Ka-Wai Wan, Senior Quality and Pharmaceutical Assessor, Medicines and Healthcare products Regulatory Agency, Marija Sajic, Pre Clinical Assessor, Medicines and Healthcare Products Regulatory Agency (MHRA), Markus Bergmann, Vice President, CureVac SE, Michael Anyadiegwu, CMC Technology Lead, CEPI, Prasun Chakraborty, CEO and Founder, Genevation LTD., Sophia Hundt, Principal Scientist, Ceva Animal Health, Sukrut Somani, Director - Chemistry Manufacturing and Controls, BioNTech, Zoltán Kis, Senior Lecturer (Associate Professor), University of Sheffield

Venue details: Hotel Palace Berlin, 45 Budapester Straße, Berlin, 10787, Germany